Activation of the c-Jun N-terminal Kinase /Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs

Improved therapies are needed for non-small cell lung cancer. Diazeniumdiolate-based nitric oxide (NO)–releasing prodrugs are a growing class of promising NO-based therapeutics. Recently, we have shown that O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Maciag, Anna E., Nandurdikar, Rahul S., Hong, Sam Y., Chakrapani, Harinath, Diwan, Bhalchandra, Morris, Nicole L., Shami, Paul J., Shiao, Yih-Horng, Anderson, Lucy M., Keefer, Larry K., Saavedra, Joseph E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3422893/
https://ncbi.nlm.nih.gov/pubmed/22003962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm2004128
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge